Latest news with #Ensure
Yahoo
17-07-2025
- Business
- Yahoo
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat
Abbott Laboratories ABT reported second-quarter 2025 adjusted earnings per share (EPS) of $1.26, which beat the Zacks Consensus Estimate by 0.8%. The figure improved 10.5% from the prior-year quarter's level. GAAP EPS was $1.01 compared with 74 cents in the second quarter of 2024. Following the earnings announcement, ABT stock fell 5% at pre-market trading today. The share price drop might be due to its reserved third-quarter guidance, which came in slightly below the Zacks Consensus Estimate. ABT's Q2 Revenues Worldwide sales of $11.14 billion were up 7.4% year over year on a reported basis. The top line surpassed the Zacks Consensus Estimate by 0.6%. Organically, sales improved 6.9% year over year. Organic sales, ex-COVID rose 7.5% year over year. ABT's Q2 Results in Detail Abbott operates through four segments — Established Pharmaceuticals, Medical Devices, Nutrition and Diagnostics. Established Pharmaceuticals' product sales increased 6.9% on a reported basis (7.7% on an organic basis) to $1.38 billion. Organic sales in key emerging markets improved 8.7% year over year. This was led by double-digit growth in several countries, including Asia, Latin America and the Middle East. In the second quarter, the Medical Devices segment's sales rose 13.4% year over year on a reported basis (12.2% organically) to $5.37 billion. Sales growth was led by Diabetes Care, Structural Heart and Heart Failure and Electrophysiology. Several products, including FreeStyle Libre, Navitor, TriClip, and AVEIR, contributed to the strong performance. The Diabetes Care division reported organic sales growth of 19.6% year over year, led by sales of continuous glucose monitors, which accounted for $1.90 billion of total sales. Structural Heart sales rose 11.7%, and Heart Failure sales improved 14% year over year organically. The Vascular division recorded organic sales growth of 3.5%. The Electrophysiology, Rhythm Management and Neuromodulation divisions recorded organic growth of 10.3%, 9.8% and 4.3%, respectively, in the quarter under review. For the second quarter, Nutrition sales rose 2.9% year over year on a reported basis (up 3.4% organically) to $2.21 billion. Pediatric Nutrition sales were up 0.2%, and Adult Nutrition sales improved 6.6% organically. According to the company, Adult Nutrition sales benefited from the strong global growth of Ensure and Glucerna, Abbott's market-leading brands. For the second quarter, Diagnostics sales declined 1% year over year on a reported basis (down 1.4% organically) to $2.17 billion. Organic sales, ex-COVID, rose 0.8%. Core Laboratory Diagnostics sales were up 1.6% organically. Molecular Diagnostics' sales declined 3.4% on an organic basis. Rapid Diagnostics sales were down 6.8%. Point of Care Diagnostics sales decreased 5.2%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Margin Details of ABT In the second quarter, the gross profit rose 8.9% year over year to $6.29 billion despite a 5.4% increase in the cost of products sold (excluding amortization expense). The gross margin expanded 79 basis points (bps) to 56.4%. Selling, general and administration expenses rose 5.3% year over year to $3.09 billion. Research and development expenses rose 3.9% year over year to $725 million. The company reported an adjusted operating profit of $2.47 billion, up 15.5% year over year. Also, the adjusted operating margin expanded 156 bps to 22.2%. ABT's 2025 Financial Guidance Abbott expects full-year adjusted diluted EPS to be in the range of $5.10-$5.20 (earlier $5.05-$5.25). The Zacks Consensus Estimate for the metric is pegged at $5.16. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote Full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, is expected to be in the range of 7.5-8.0%, or 6.0-7.0% when including COVID-19 testing-related sales. The Zacks Consensus Estimate for sales is currently pegged at $44.70 billion, suggesting a 6.6% improvement from the 2024 level. For the third quarter of 2025, adjusted diluted EPS is expected to be between $1.28 and $1.32. The Zacks Consensus Estimate for the metric is pegged at $1.34. Our Take Abbott exited the second quarter of 2025 with better-than-expected results. Both its earnings and revenues beat their respective estimates. Additionally, the figures improved on a year-over-year basis. All business segments experienced growth during the reported quarter, except Diagnostics. Meanwhile, Abbott's Diagnostics sales growth continued to be adversely impacted by year-over-year declines in COVID-19 testing-related sales, along with volume-based procurement programs in China. During the reported quarter, Abbott announced favorable data from the AVEIR Conduction System Pacing (CSP) clinical feasibility study. Additionally, the company received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR) system — a first-of-its-kind device to help treat people with mitral valve disease. Meanwhile, Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia, expected to be completed by 2028. In addition, the expansion of both margins is encouraging. ABT's Zacks Rank and Other Key Picks Abbott currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the broader medical space are Veeva Systems VEEV, Intuitive Surgical ISRG and Boston Scientific BSX. Veeva Systems, currently sporting a Zacks Rank #2, reported first-quarter fiscal 2026 adjusted EPS of $1.97, which surpassed the Zacks Consensus Estimate by 13.2%. Revenues of $759 million beat the consensus mark by 4.3%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. VEEV has an estimated long-term earnings growth rate of 23.3% compared with the industry's 19.1%. The company beat on earnings in each of the trailing four quarters, the average surprise being 10%. Intuitive Surgical, carrying a Zacks Rank #2 at present, posted first-quarter 2025 adjusted EPS of $1.81, which exceeded the Zacks Consensus Estimate by 5.9%. Revenues of $2.25 billion surpassed the Zacks Consensus Estimate by 3.3%. ISRG has an estimated long-term earnings growth rate of 15.1% compared with the industry's 14.4%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.6%. Boston Scientific, carrying a Zacks Rank #2, reported a first-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 0.1%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 20.9%. BSX has a long-term earnings growth rate of 13.2% compared with the industry's 13.9%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-07-2025
- Business
- Yahoo
Medical Insurers and Pharma Firms' Stock Slipped Thursday. Here's Why.
Key Takeaways Health insurance firms were some of Thursday's worst-performing stocks in both the S&P 500 and Dow Jones Industrial Average. Elevance Health shares plunged after the insurer lowered its outlook because of what CEO Gail Boudreaux called an 'unprecedented cost trend." Investors appeared to lose confidence in other companies that sell health insurance, as well as pharmaceutical insurers and pharmaceutical companies' stock fell Thursday, weighed down by Elevance's downbeat outlook and other factors. Health care was the worst-performing sector in the S&P 500 Thursday, while the index—and nearly all the other sectors within it—was on track to post modest gains. UnitedHealth Group (UNH), which provides health insurance and other services, was the worst-performing stock in the Dow Jones Industrial Average. Elevance Health (ELV) shares plunged 12%, making it the worst-performing stock in the S&P 500. The medical insurer lowered its outlook for a second consecutive year because of an 'unprecedented cost trend affecting multiple lines of business,' CEO Gail Boudreaux said on a conference call, according to a transcript from AlphaSense. Investors responded by selling other medical insurers' shares, with shares of Molina Healthcare (MOH) recently falling about 5%, of Centene Corp. (CNC) dropping 5% and of Cigna Group (CI) dipping 2%. UnitedHealth was down about 1%. Centene pulled its full-year guidance in early July, while UnitedHealth pulled its outlook in May. Some investors also appeared to sour on pharmaceutical companies. Shares of Abbott Laboratories (ABT), which makes medicine and nutritional products like Ensure, were recently down nearly 8%. Abbott narrowed its outlook for the year, noting declining demand for COVID-19 tests. Shares of the pharmaceutical company Eli Lilly (LLY) were recently off by 3% Read the original article on Investopedia
Yahoo
02-05-2025
- Climate
- Yahoo
Murrysville residents fight to save food from spoiling, push through another day without power
Hundreds of people in Murrysville remain without power Friday evening, more than three days after storms caused widespread damage on Tuesday. A cooler inside Gertrude Laughrey's home is filled with milk, yogurt, Ensure, and eggs. 'At $5 a dozen, I guess you better save those,' Laughrey said to Channel 11's Andrew Havranek. She and her husband have been without power since Tuesday's storm. She's tried to save as much as she could from the fridge and has another bin full of ice with waters and meals. Those meals were sent from her husband's health insurance on Thursday. He's been in and out of the hospital and nursing homes. 'It'll have to do,' Laughrey said. She's had to cancel nurse visits for her husband because she doesn't have power for them to hook things up. They also run water from two wells. Because they don't have power, they don't have running water. 'We can't even flush our commodes,' Laughrey said. 'This morning, I took a hanger and fished out the toilet tissue and put it in a bag and put it in the trash. I can't let them fill up like that. I'll never be able to flush them.' She's not alone. Homes all around her neighborhood off of Sardis Road are dark, including a home where a tree snapped. The homeowner didn't want to share his name or show his face on camera, but he showed Channel 11's Andrew Havranek his basement, where he has a cooler hooked up to a generator to keep 300 pounds of meat fresh. 'There's turkey, there's deer, [my son] buys from the farm market all kinds of beef,' he said. He was able to get the last generator at a local store in Murrysville on Tuesday night. On Friday, crews with First Energy were working on a substation in the woods between his house and Laughrey's. 'The transmission line was damaged, and we've been working very hard to get that back on,' said Todd Meyers, spokesperson for First Energy. Meyers said First Energy has crews from all over the region and other states helping out, and say power should be restored to most people in the Murrysville area either by the end of Saturday or by Monday. Laughrey can't wait. 'It's like living in a primitive world,' she said. Download the FREE WPXI News app for breaking news alerts. Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW
